Stay updated on A-dmDT390-bisFv & Pembrolizumab in Melanoma Clinical Trial

Sign up to get notified when there's something new on the A-dmDT390-bisFv & Pembrolizumab in Melanoma Clinical Trial page.
Latest website image capture
Clouds background image

Latest updates to the A-dmDT390-bisFv & Pembrolizumab in Melanoma Clinical Trial page

  1. Check
    3 days ago
    Change Detected
    Summary
    Revision from v3.5.0 to v3.5.2.
    Difference
    0.1%
    Check dated 2026-04-17T14:14:59.000Z thumbnail image
  2. Check
    10 days ago
    No Change Detected
  3. Check
    17 days ago
    No Change Detected
  4. Check
    32 days ago
    Change Detected
    Summary
    - Revision: v3.5.0 implemented. - Previous revision: v3.4.3 removed. - No visible changes to study details or page content.
    Difference
    0.1%
    Check dated 2026-03-20T00:22:17.000Z thumbnail image
  5. Check
    39 days ago
    Change Detected
    Summary
    Revision label updated from v3.4.2 to v3.4.3. No substantive content changes observed.
    Difference
    0.1%
    Check dated 2026-03-12T20:39:38.000Z thumbnail image
  6. Check
    68 days ago
    Change Detected
    Summary
    Revision: v3.4.2 is now displayed on the page, replacing the previous Revision: v3.4.1. To avoid being alerted by small changes, set an alert condition by clicking below.
    Difference
    0.1%
    Check dated 2026-02-12T01:17:35.000Z thumbnail image
  7. Check
    75 days ago
    Change Detected
    Summary
    Revision history updated: Revision: v3.4.1 was added and Revision: v3.4.0 was removed. To avoid being alerted by small changes, set an alert condition by clicking below.
    Difference
    0.1%
    Check dated 2026-02-05T00:55:05.000Z thumbnail image
  8. Check
    82 days ago
    Change Detected
    Summary
    Added a glossary toggle and updated study record metadata to include 'Last Update Submitted that Met QC Criteria' and a new revision label (Revision: v3.4.0). Removed or reformatted older QC-related text such as 'Last Update Submitted that met QC Criteria' and 'No FEAR Act data'.
    Difference
    0.2%
    Check dated 2026-01-28T21:15:48.000Z thumbnail image

Stay in the know with updates to A-dmDT390-bisFv & Pembrolizumab in Melanoma Clinical Trial

Enter your email address, and we'll notify you when there's something new on the A-dmDT390-bisFv & Pembrolizumab in Melanoma Clinical Trial page.